Eyeworld

48 | EYEWORLD | FALL 2025 C ORNEA by Julie Schallhorn, MD Cornea Editor antibody drug conjugates. These drugs have amazing potential to treat a wide variety of illness in a targeted fashion, but many of them can induce significant ocular surface toxicity. As this type of therapy becomes more common, we will see more patients suffering from the side effects, making this article a must-read for every ophthalmologist. The other two articles are likewise helpful. With a myriad of new therapies, the manage- ment of Sjögren's has undergone substantial change, and we have an excellent article with outstanding experts discussing this. There's also a nice overview of the role of pinhole apertures in the management of irregular corneas, with helpful implementation tips. Enjoy reading this issue! I graduated from UCLA with my bachelor's degree in 2003. During my junior year, one of my dear friends started experiencing an array of bizarre phenomena: Common colds would keep him in bed for days, and the slightest bump would leave a goose egg. When one of his bruises became infected and turned into cellulitis, he finally went to see a doctor. The diagnosis was chronic myeloid leukemia (CML). Prior to 2001, this would have been life altering, if not fatal. The course was this: The CML would invariably experience a further mutation and turn into acute myeloid leukemia, which would require a bone marrow transplant with high risks of graft versus host disease, relapse, and death. However, the first can- cer-specific targeted therapy, imatinib mesylate, had just been approved. He started this and was back in class within a week, graduating on time with the rest of us. Today he lives in California, is married, and is the proud father of two ador- able kids. As new therapies become available, this type of story is being repeated over and over again. As medicine ventures into new territory, we learn more about treatments and the side effects they bring. The human body is a complex system, and fixing one problem can often induce another. One of this quarter's articles is an outstanding overview of corneal side effects of the next generation of cancer-specific therapies: Above and beyond As medicine ventures into new territory, we learn more about treatments and the side effects they bring. The human body is a complex system, and fixing one problem can often induce another. Dagny Zhu, MD, EyeWorld Cataract Editorial Board member, shared some of the ways she goes "beyond the routine," including office-based cataract surgery, immediate sequential bilateral cataract surgery, oral sedation for cataract surgery, offering a presbyopia-correcting IOL as the default choice for patients who qualify, opting out of insurance, repeating biometry and topography on the day of surgery, and treating dryness with oral supplements. B E Y O ND T H E R O U T I N E

• Blank Page
• Blank Page (1)